Agents under investigation for the treatment and prevention of neutropenia.
Neutropenia, and most notably febrile neutropenia, represents a significant complication following chemotherapy administration. Present agents used for the treatment of neutropenia include G-CSF, GM-CSF and G-CSF conjugated to polyethylene glycol (PEG) as pegylated G-CSF. Despite the availability and considerable efficacy of the above approved agents in reducing the risk of neutropenia and its complications remain significant issues in oncology. This article explores some of the biology behind the colony-stimulating factors and the recent advances in agents for the treatment and prevention of neutropenia, including the development of additional G-CSF agonists, chemoprotectants, retinoic receptor agonists and CXC chemokine receptor 4 antagonists.
Huston
Alissa
A
University of Rochester, James P Wilmot Cancer Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA.
Lyman
Gary H
GH
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors; D016188:Receptors, Granulocyte Colony-Stimulating Factor / Q000819:agonists / Q000378:metabolism; D016187:Receptors, Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism; D018168:Receptors, Retinoic Acid / Q000819:agonists
D000970:Antineoplastic Agents; D019718:Receptors, CXCR4; D016188:Receptors, Granulocyte Colony-Stimulating Factor; D016187:Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; D018168:Receptors, Retinoic Acid; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor